Search

“Nothing about us without us”: how patient advocacy is changing the game

Nuno Borges MBBS MRes, on behalf of YoungEHA
When it comes to advancing medical care, there is no denying that patients are at the core of everything we do.

Read more

Patient Advocacy Committee

Current committee members
Derek Elston, United Kingdom (Chair)
Samantha Nier, Switzerland (Vice-chair)
Loris Brunetta, Italy (Vice-chair)
Members representing a Patient Advocacy Organization

Organization
Member

Acute Leukaemia Advocates Network (ALAN)

Samantha Nier

CCI Europe

Anita Kienesberger

CLL Advocates Network (CLLAN)

Pierre Aumont

CML Advocates Network

Jan Geissler

European Federation of Associations of Patients with Haemochromatosis (EFAPH)

Dag…

Read more

EPICOVIDEHA survey

COVID-19 infections in patients with Hematological Malignancies - Results from EHA-IDWP registry
EPICOVIDEHA is an international open web-based registry for patients with haematological malignancies infected with SARS-CoV-2,
The survey has been approved by the Institutional Review Board and Ethics Committee of the…

Read more

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

EHA Blood Cancer Awareness Month Wrap-up

The first European Hematology Association (EHA) Blood Cancer Awareness Month digital campaign aimed to raise awareness of hematological malignancies and EHA’s commitment “towards a cure for all blood disorders”.

Read more

Highlights of Past EHA (HOPE) Asia 2020

EHA is returning to Sri Lanka for the 2nd edition of the Highlights of Past EHA (HOPE) Asia, organized with our hosting partner: the Sri Lanka College of Haematologists (SLCH).

Read more

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more